TIDMCLIN
Clinigen Group plc
17 July 2018
RNS Reach
17 July 2018
Clinigen acquires global rights to Proleukin(R)
outside the United States
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, has acquired the global
rights to Proleukin(R) (aldesleukin, recombinant interleukin-2)
outside the United States from Novartis. Financial details have not
been disclosed.
Proleukin(R) is licensed in around 20 countries around the world
and is primarily indicated for use in metastatic renal cell
carcinoma, as well as for metastatic melanoma in certain markets.
In addition, Proleukin(R) is currently being investigated in
clinical trials at varying dose levels and in combination with
other licensed and developmental pharmaceutical products.
Clinigen will seek to revitalise sales of Proleukin(R) by
working with Health Care Professionals to ensure its benefit to
patients is well understood and by making the medicine available to
those who need it through the Group's global distribution network
for both licensed and unlicensed supply. The Group is also
investigating the opportunity to develop new dosage presentations
and potential product combinations.
The acquisition of Proleukin(R) is a good fit with the Group's
current Commercial Medicines portfolio of products in the oncology
and infectious disease therapy areas.
Shaun Chilton, Group Chief Executive Officer, Clinigen,
said:
"This acquisition strengthens our offering in Commercial
Medicines and brings our specialty pharma product portfolio to six.
It demonstrates our strategy of acquiring global rights to assets
with the aim of revitalising and returning them back to the
broadest possible access, whilst also supporting their use in new
and emerging treatment regimens."
David Bryant, Chief Business Officer, Clinigen, said:
"Proleukin is an important medicine that has demonstrated
complete responses in some patients, with evidence of cancer free
survival over 15 years. We believe that its use in emerging
treatment regimens will continue to help people fight cancer for
years to come."
The Group has also announced its year end trading update today -
see separate press release.
- Ends -
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
David Bryant, Chief Business Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black / Tom Ballard (Corporate
Broking)
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Alex Shaw / Email: clinigen@instinctif.com
Deborah Bell
Notes to Editors
About Proleukin(R) (aldesleukin)
Proleukin(R) (aldesleukin) is indicated for the treatment of
adults with metastatic renal cell carcinoma (metastatic RCC). In
certain markets Proleukin is also indicated for the treatment of
adults with metastatic melanoma. Careful patient selection is
mandatory prior to the administration of Proleukin.
Evaluation of clinical studies to date reveals that patients
with more favourable ECOG performance status (ECOG PS 0) at
treatment initiation respond better to Proleukin, with a higher
response rate and lower toxicity. Therefore, selection of patients
for treatment should include assessment of performance status.
Experience in patients with ECOG PS >1 is extremely
limited.
About metastatic renal cell carcinoma (metastatic RCC)
Renal cell carcinoma, also called kidney cancer, occurs when
cancer cells form in the tubules of the kidney. Tubules are tiny
tubes in your kidney that help filter waste products from your
blood in order to make urine.
Smoking, hypertension, obesity, and hepatitis C all increase the
risk of renal cell carcinoma. Renal cell carcinoma becomes
metastatic renal cell carcinoma when it spreads beyond your kidney
to your lymph system, bones, or other organs.
About metastatic melanoma
Melanoma is the rarest and most dangerous type of skin cancer.
It begins in the melanocytes, which are the cells in your skin that
produce melanin. Melanin is the pigment responsible for skin
colour. Melanoma develops into growths on your skin, which often
resemble moles. These growths or tumours may also come from
existing moles. Melanomas can form on skin anywhere on your body,
including inside the month or vagina.
Metastatic melanoma occurs when the cancer spreads from the
tumour to other parts of your body. This is also known as stage 4
melanoma. Melanoma is the most likely of all skin cancers to become
metastatic if not caught early.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply
and management of quality-assured comparator medicines and services
to clinical trials and Investigator Initiated Trials.
Unlicensed Medicines
Clinigen is the global leader in ethically sourcing and
supplying unlicensed medicines to hospital pharmacists and
physicians for patients with a high unmet medical need. The Group
manages early access programmes to innovative new medicines and
provides 'on demand' access globally to medicines which remain
unlicensed at the point of care.
Commercial Medicines
Clinigen acquires global rights to niche hospital only and
critical care products, revitalising these assets around the world
and returning them back to sustained growth. It also provides
access to licensed and branded generic medicines in the Africa and
Asia Pacific region.
The Group also has an 'unlicensed to licensed' strategy, where
it looks to take unlicensed medicines with commercial potential and
licence them, helping to address unmet medical need and allowing
the Group to capitalise on its market-leading positions.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASFAFIMFASESW
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024